Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-214870 in photosensitive epilepsy
NCT04241965Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Feb 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind trial of OPC-214870 in photosensitive epilepsy (PSE), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Change in Standardized Photosensitivity Range up to 3 days. Started Feb 2020; status: completed.
02
Drugs
OPC-214870
03
Conditions
photosensitive epilepsy (PSE)
Beyond the preview
Go deeper on NCT04241965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04241965.